155 related articles for article (PubMed ID: 30987640)
1. RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.
Mesci A; Lucien F; Huang X; Wang EH; Shin D; Meringer M; Hoey C; Ray J; Boutros PC; Leong HS; Liu SK
J Transl Med; 2019 Apr; 17(1):125. PubMed ID: 30987640
[TBL] [Abstract][Full Text] [Related]
2. RSPO3 is a marker candidate for predicting tumor aggressiveness in ovarian cancer.
Gu H; Tu H; Liu L; Liu T; Liu Z; Zhang W; Liu J
Ann Transl Med; 2020 Nov; 8(21):1351. PubMed ID: 33313096
[TBL] [Abstract][Full Text] [Related]
3. RSPO3 promotes the aggressiveness of bladder cancer via Wnt/β-catenin and Hedgehog signaling pathways.
Chen Z; Zhou L; Chen L; Xiong M; Kazobinka G; Pang Z; Hou T
Carcinogenesis; 2019 Apr; 40(2):360-369. PubMed ID: 30329043
[TBL] [Abstract][Full Text] [Related]
4. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer.
Piao YR; Piao LZ; Zhu LH; Jin ZH; Dong XZ
Asian Pac J Cancer Prev; 2013; 14(6):3897-901. PubMed ID: 23886204
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
7. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis.
Chien MH; Lin YW; Wen YC; Yang YC; Hsiao M; Chang JL; Huang HC; Lee WJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):246. PubMed ID: 31182131
[TBL] [Abstract][Full Text] [Related]
8. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
10. The metastasis suppressor CD82/KAI1 represses the TGF-β
Lee MS; Lee J; Kim YM; Lee H
Prostate; 2019 Sep; 79(12):1400-1411. PubMed ID: 31212375
[TBL] [Abstract][Full Text] [Related]
11. P21 activated kinase-1 mediates transforming growth factor β1-induced prostate cancer cell epithelial to mesenchymal transition.
Al-Azayzih A; Gao F; Somanath PR
Biochim Biophys Acta; 2015 May; 1853(5):1229-39. PubMed ID: 25746720
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
13. Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness.
Gong X; Yi J; Carmon KS; Crumbley CA; Xiong W; Thomas A; Fan X; Guo S; An Z; Chang JT; Liu QJ
Oncogene; 2015 Sep; 34(36):4692-701. PubMed ID: 25531322
[TBL] [Abstract][Full Text] [Related]
14. miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells.
Liu C; Guan H; Wang Y; Chen M; Xu B; Zhang L; Lu K; Tao T; Zhang X; Huang Y
PLoS One; 2015; 10(12):e0144073. PubMed ID: 26650737
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
Cao W; Li F; Yao J; Yu J
BMC Cancer; 2015 Nov; 15():915. PubMed ID: 26582057
[TBL] [Abstract][Full Text] [Related]
16. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis.
Yi C; Wan X; Zhang Y; Fu F; Zhao C; Qin R; Wu H; Li Y; Huang Y
Int J Biochem Cell Biol; 2018 Sep; 102():138-150. PubMed ID: 30053504
[TBL] [Abstract][Full Text] [Related]
17. Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.
Chakravarthi BV; Goswami MT; Pathi SS; Dodson M; Chandrashekar DS; Agarwal S; Nepal S; Hodigere Balasubramanya SA; Siddiqui J; Lonigro RJ; Chinnaiyan AM; Kunju LP; Palanisamy N; Varambally S
Prostate; 2017 Jan; 77(1):10-21. PubMed ID: 27550065
[TBL] [Abstract][Full Text] [Related]
18. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
[TBL] [Abstract][Full Text] [Related]
20. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
